TenSixteen Bio
San Francisco, United States · Founded 2021 · $40.0M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Website
- tensixteen.bio
- Total Funding
- $40.0M
- Last Round
- $40.0M Series AJan 2022
- Rounds
- 1
About
Precision platform therapeutics company targeting somatic mosaicism and DNA changes across multiple disease areas.
Summary
TenSixteen Bio is a Biotech company based in San Francisco, United States, founded in 2021. It has raised $40.0M in total across 1 round, most recently a $40.0M Series A round in Jan 2022. Investors include Foresite Capital and GV.
Tech & App Stack
1 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...